Author + information
- Orhan Demir,
- Serdar Sevimli,
- Hüsnü Değirmenci,
- Hakan Duman,
- Eftal Murat Bakırcı,
- Selami Demirelli and
- Hikmet Hamur
Atherosclerotic heart diseases continue to be the most important cause of death in developed countries. Hyperlipidemia is the most crucial risk factor in atherosclerosis development. The statins used in hyperlipidemia treatment play an essential role in reducing the morbidity and mortality associated with atherosclerosis. There are numerous studies on old generation statins and new generation statins; however, there are limited number of studies comparing these two groups. Therefore, we aimed to present this study to the literature and determine the dose efficacy of hypolipidemic agents by comparing the old generation statin simvastatin to new generation statins (atorvastatin, rosuvastatin).
This study is a clinical, prospective cohort study. A total of 160 subjects (76 women and 84 men) who applied to our clinic from November 2011 to May 2011 and were indicated for medicinal treatment according to National Cholesterol Education Programme Adult Treatment Panel (NCEP ATP) 3 criteria despite the four week long first line diet were included in the study. Following the evaluation of lipid profiles based on medical history, physical examination, and clinical and laboratory findings, eligible subjects were assigned to the three groups according to simvastatin dose (10 mg, 20 mg, 40 mg/day), three groups according to atorvastatin dose (10 mg, 20 mg, 40 mg/day) two groups according to rosuvastatin dose (10 mg, 20 mg/day). Thus, a total of 8 groups were generated. There were 20 patients in each group. In our study, the subjects were evaluated with clinical and laboratory methods at baseline and after 6 weeks of treatment.
The mean age of the 160 patients enrolled for the study was 58.95±10.22 (37 to 82). There was no difference between the groups with regards to demographic characteristics. The reduction in low-density lipoprotein (LDL) cholesterol was 28-40% (10-40 mg/day) with simvastatin, 39-51% (10-40 mg/day) with atorvastatin and 50-60% (10-20 mg/day) with rosuvastatin after 6 weeks of treatment (p<0.01). The increase in high-density lipoprotein (HDL) cholesterol at week 6 compared to baseline was most prominent in the rosuvastatin (20 mg/day) group.
We detected that the hypolipidemic effects of rosuvastatin and atorvastatin were more prominent compared to simvastatin. This supports the idea that new generation statins may be used in clinical practice to a further extent compared to old generation statins. Furthermore, based on the findings of our study it can be concluded that rosuvastatin may be the preferred choice of treatment in hyperlipidemia patients with low levels of HDL-C.